NextCure, Inc. — Form 8-K
Filed September 25, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 82/100
What the filing says
NextCure (market cap ~$12.6M) filed a Delaware Chancery Court petition on Sept 14, 2026 seeking judicial validation of a 1:12 reverse stock split (2025 Reverse Split Amendment) that became effective July 14, 2025. The split was approved by 64.76% of outstanding shares (18.2M votes for, 2.0M against, out of ~28M shares), meeting the "Votes Cast" standard under Delaware law. However, it fell short of the 66.67% supermajority required by the company's charter if that higher threshold applies to reverse splits. Subsequent Delaware law amendments (effective Aug 2026) created ambiguity about which voting standard governed. The company now faces uncertainty over share validity ahead of a planned merger with Avere Therapeutics (closing target: Nov 2026) and prior equity financings (Simcere, November PIPE, ATM offering totaling ~$14.5M) executed in reliance on split validity.
Why this rating
Existential threat: if 2025 split invalidated, capitalization structure collapses, prior financings and pending merger jeopardized, delisting risk, and stock ownership untraceable. Represents ~100% of current market value uncertainty.
Price action (we called it negative)
before filing · preread $5.08 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from September 25, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.